Saturn V Capital Management LP Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001964437

What is a 13F filing? Who files one and when · What 13F filings can't tell you

SmallFocusedHealth TiltHigh Turnover how tags are computed

Q2 2026 · 23 positions · Total reported value $697.47M · Top-10 concentration 75.6% · Updated 2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

Turnover: 41.7% · 3 new · 6 cut · 1 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q1 2026 → Q2 2026): +18.2% · vs SPY +3.4% · Prev Value $552.22M — last quarter positions weighted by this quarter price moves · ranking

In its Q2 2026 13F filing, Saturn V Capital Management LP disclosed 23 equity positions with a combined reported value of $697.47M. The filing implies a focused portfolio: its ten largest positions account for 75.6% of reported value. HoldingsHub classifies the profile as Small / Focused / Health Tilt / High Turnover.

The largest disclosed positions as of Q2 2026 were AMLX ($83.05M), ALMS ($82.04M), ABVX ($69.14M). By sector, the heaviest allocations are Health Care 100.0%.

Versus the prior quarter, Saturn V Capital Management LP opened 3 new positions, trimmed 6 and fully exited 1, a turnover rate of 41.7% of positions. The portfolio's overlap with the prior quarter was 83% of names.

The largest new positions opened in Q2 2026 were TRVI ($19.62M), SGMT ($11.44M), VIR ($7.85M).

Of the 1 positions fully exited versus the prior quarter, the largest were COGT ($24.12M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q2 2026)

  • TRVI TREVI THERAPEUTICS INC · $19.62M
  • SGMT SAGIMET BIOSCIENCES INC A · $11.44M
  • VIR VIR BIOTECHNOLOGY INC · $7.85M

Fully Exited (vs previous quarter)

  • COGT COGENT BIOSCIENCES INC · prev qtr: $24.12M

Insider Transactions (Form 4)

Latest Saturn V Capital Management LP buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

Saturn V Capital Management LP, based in Austin, TX, United States, files quarterly US equity holdings with the SEC on Form 13F. Its latest filing (Q2 2026) lists 23 positions worth $697.47M in total. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).

Firm Snapshot

  • Headquarters: AUSTIN, TX, United States
  • SEC registration: 801-128448 (status: Approved), registered 2023-07-27
  • Regulatory AUM (Form ADV): $793.21M as of 2026-08-04
  • Client mix (by RAUM): pension and profit-sharing plans 100%
  • Manages 3 private funds, of which 3 hedge funds

Portfolio Structure

  • 23 positions · $697.47M reported value (Q2 2026)
  • Top 10 holdings = 75.6% of reported value
  • Largest position: AMLX (AMYLYX PHARMACEUTICALS INC) at 11.9%
  • Average position size: $30.32M

Sector Tilt

  • Health Care 100.0%
  • (classified holdings cover 100% of value)

Quarterly Activity

  • Q2 2026: 3 new, 12 added, 6 reduced, 1 exited
  • 2 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

AI Rebalance Analysis

1. Overall Direction and Market View: Saturn V Capital Management LP appears to be maintaining a cautious approach with a focus on healthcare sector. The addition of new positions suggests a belief in the sector's potential, but the reduction in several existing holdings indicates a conservative stance with a willingness to pare back exposure to certain names. 2. Key Moves: - Additions: The fund added to positions in AMYLYX PHARMACEUTICALS (AMLX), VAXCYTE INC (PCVX), IMMIX BIOPHARMA INC (IMMX), PHARVARIS N V (PHVS), CELCUITY INC (CELC), DISC MEDICINE INC (IRON), and CANDEL THERAPEUTICS INC (CADL). The largest increase was in IMMX, which saw a 26.1% quarterly share increase. - Reductions: The fund reduced its holdings in ALUMIS INC (ALMS), ABIVAX SA (ABVX), JAZZ PHARMACEUTICALS PLC (JAZZ), and CELCUITY INC (CELC). The most significant reduction was in ALMS, with a 9.0% decrease in shares. 3. Portfolio Structure: The portfolio is active, with a strong sector bias towards healthcare. The fund's risk appetite seems moderate, as indicated by the addition of several new positions but also by the reduction of some existing ones. There is a mix of active management in picking specific stocks and some passivity in holding a diversified basket of healthcare companies. 4. Per-Holding One-Liner: - AMLX: AMYLYX PHARMACEUTICALS INC – Biopharmaceutical company focused on rare and orphan diseases. - ALMS: ALUMIS INC – Biotechnology company developing novel treatments for cancer. - ABVX: ABIVAX SA – Biotechnology company focusing on infectious diseases. - PCVX: VAXCYTE INC – Biopharmaceutical company focusing on cancer immunotherapy. - IMMX: IMMIX BIOPHARMA INC – Biotechnology company working on novel treatments for various diseases. - PHVS: PHARVARIS N V – Biotechnology company focusing on drug discovery and development. - JAZZ: JAZZ PHARMACEUTICALS PLC – Biopharmaceutical company specializing in neuroscience and pain. - CELC: CELCUITY INC – Biotechnology company focusing on cellular immunotherapy for cancer. - IRON: DISC MEDICINE INC – Biotechnology company focusing on cancer and inflammation. - CADL: CANDEL THERAPEUTICS INC – Biotechnology company developing therapies for oncology and rare diseases. 5. One-Sentence Style Summary: Saturn V Capital Management LP maintains a conservative approach in healthcare, adding to promising biotech names while trimming exposure to some existing holdings, indicating a focus on selective growth opportunities.

Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice.

Sector Allocation

Health Care 100.0%
Sort by: Value Shares Weight Sector Change · CSV
# Shares Value Weight Allocation Change
1 4.62M $83.05M 11.91%
11.91%
Add
2 2.92M $82.04M 11.76%
11.76%
Reduce
3 518.87K $69.14M 9.91%
9.91%
Reduce
4 852.91K $49.58M 7.11%
7.11%
Add
5 4.66M $48.03M 6.89%
6.89%
Add
6 1.31M $45.44M 6.51%
6.51%
Add
7 160.94K $38.78M 5.56%
5.56%
Reduce
8 370.32K $38.74M 5.55%
5.55%
Add
9 524.73K $38.38M 5.50%
5.50%
Add
10 3.30M $34.03M 4.88%
4.88%
Add
11 6.97M $32.57M 4.67%
4.67%
Add
12 311.98K $28.89M 4.14%
4.14%
Reduce
13 1.06M $23.49M 3.37%
3.37%
Add
14 1.05M $19.62M 2.81%
2.81%
New
15 2.10M $12.40M 1.78%
1.78%
Add
16 1.48M $11.44M 1.64%
1.64%
New
17 684.88K $9.50M 1.36%
1.36%
Add
18 3.87M $7.85M 1.13%
1.13%
Hold
19 770.64K $7.85M 1.13%
1.13%
New
20 8.39M $7.32M 1.05%
1.05%
Reduce
21 182.83K $4.82M 0.69%
0.69%
Add
22 350.00K $2.72M 0.39%
0.39%
Hold
23 663.06K $1.78M 0.26%
0.26%
Reduce

Holdings Prediction Model

Predicts next-quarter Top-10 holdings and weights from the fund's own historical trading轨迹 (add / reduce / hold) plus each stock's price momentum and relative volume. Strictly no look-ahead: a prediction for quarter T+1 uses only data through quarter T. Weights are shares of the modelled portfolio.

The next-quarter predicted Top 10 (2026-Q3) is shown in the «Latest Q · Forecast» tab above, in the same holdings format. That view is for logged-in accounts: 3 views per day on Free, unlimited on Gold/Diamond.

Latest-Quarter Accuracy (2026-Q2)

P 90% R 90% F1 90% (modelled on 2026-Q1; 9/10 hit)

Low-confidence forecast This fund replaces about 24% of its Top-10 each quarter and backtests at F1 76% (threshold 80%). Holdings in high-turnover portfolios cannot be forecast from their own history; the figures below are illustrative.

Historical Backtest (10 quarters)

Avg precision 76% · recall 76% · F1 76% · avg rank error 2.6 · Top-10 turnover 24%

Quarter Prec. Recall F1 Predicted Top 10 Actual Top 10
2024-Q1 70% 70% 70% CYTK · CRNX · KALV · ARGX · ASND · AMLX · CBAY · ANAB · MRUS · BMRN CRNX · ARGX · CYTK · KALV · MRUS · IRON · ASND · ANAB · PCVX · COGT
2024-Q2 70% 70% 70% ARGX · CRNX · MRUS · IRON · CYTK · KALV · ASND · ANAB · PCVX · FOLD ARGX · IRON · CRNX · PCVX · ASND · CYTK · BMRN · COGT · CRGX · KALV
2024-Q3 60% 60% 60% ARGX · IRON · CRNX · PCVX · COGT · BMRN · ASND · CYTK · CRGX · KALV ASND · IRON · PCVX · CGON · COGT · CRGX · CYTK · PHAT · MLTX · CELC
2024-Q4 80% 80% 80% ASND · IRON · PCVX · CGON · CRGX · COGT · CYTK · PHAT · MLTX · CELC IRON · ASND · MLTX · CGON · PCVX · CYTK · CRGX · CELC · SNDX · XENE
2025-Q1 80% 80% 80% IRON · ASND · MLTX · CGON · CYTK · PCVX · CRGX · SNDX · CELC · XENE ASND · IRON · CGON · XENE · MRUS · MLTX · SNDX · CELC · COGT · PCVX
2025-Q2 70% 70% 70% ASND · IRON · MRUS · XENE · CGON · SNDX · MLTX · CELC · AMLX · PCVX JAZZ · IRON · AMLX · PCVX · COGT · CELC · CGON · XENE · DYN · MLTX
2025-Q3 80% 80% 80% AMLX · JAZZ · IRON · PCVX · COGT · CELC · XENE · CGON · DYN · MLTX ABVX · AMLX · JAZZ · DYN · COGT · PCVX · CELC · CGON · IRON · PHVS
2025-Q4 90% 90% 90% ABVX · AMLX · JAZZ · DYN · PCVX · COGT · CGON · PHVS · CELC · IRON ABVX · AMLX · COGT · JAZZ · PCVX · DYN · PHVS · CELC · ALMS · IRON
2026-Q1 70% 70% 70% ABVX · AMLX · JAZZ · COGT · PCVX · DYN · PHVS · ALMS · CELC · MNPR ALMS · AMLX · ABVX · PCVX · PHVS · IMMX · CELC · JAZZ · IRON · XFOR
2026-Q2 ★ 90% 90% 90% ALMS · AMLX · ABVX · PCVX · IMMX · PHVS · CELC · IRON · JAZZ · XFOR AMLX · ALMS · ABVX · PCVX · IMMX · PHVS · JAZZ · CELC · IRON · CADL

★ = latest filed quarter (predicted vs actual). Recall = share of the real Top 10 caught by the model; precision = share of the predicted Top 10 that were real.

FAQ

What did Saturn V Capital Management LP buy in 2026-Q2?

In its 2026-Q2 13F filing, Saturn V Capital Management LP reported 23 equity positions worth $697.47M in aggregate; its largest disclosed positions were AMLX ($83.05M), ALMS ($82.04M), ABVX ($69.14M).

How large is Saturn V Capital Management LP's portfolio?

Saturn V Capital Management LP reported $697.47M of long equity holdings across 23 positions as of 2026-Q2. Top-10 holdings account for 75.6% of reported value.

What is Saturn V Capital Management LP's investment style?

HoldingsHub classifies the portfolio as Small / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/saturn-v-capital-management/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →